GAMMA Investing LLC Boosts Holdings in Moderna, Inc. (NASDAQ:MRNA)

GAMMA Investing LLC grew its position in Moderna, Inc. (NASDAQ:MRNA) by 6,981.7% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 224,702 shares of the company’s stock after buying an additional 221,529 shares during the period. GAMMA Investing LLC owned approximately 0.06% of Moderna worth $6,370,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in MRNA. FMR LLC grew its holdings in shares of Moderna by 7.4% in the fourth quarter. FMR LLC now owns 18,664,634 shares of the company’s stock worth $776,075,000 after purchasing an additional 1,282,469 shares during the last quarter. Theleme Partners LLP grew its stake in shares of Moderna by 1.0% during the 4th quarter. Theleme Partners LLP now owns 7,306,861 shares of the company’s stock worth $303,819,000 after purchasing an additional 72,028 shares during the period. Geode Capital Management LLC increased its holdings in Moderna by 2.4% in the 4th quarter. Geode Capital Management LLC now owns 7,241,354 shares of the company’s stock worth $300,219,000 after acquiring an additional 171,774 shares in the last quarter. Invesco Ltd. increased its holdings in Moderna by 24.3% in the 4th quarter. Invesco Ltd. now owns 5,006,462 shares of the company’s stock worth $208,169,000 after acquiring an additional 979,858 shares in the last quarter. Finally, Norges Bank acquired a new stake in Moderna during the 4th quarter worth $163,833,000. 75.33% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the stock. JPMorgan Chase & Co. cut their price target on shares of Moderna from $33.00 to $26.00 and set an “underweight” rating on the stock in a research note on Thursday, May 22nd. Morgan Stanley cut their price objective on Moderna from $39.00 to $32.00 and set an “equal weight” rating for the company in a research report on Wednesday, April 9th. Citigroup assumed coverage on Moderna in a research report on Thursday, March 13th. They set a “neutral” rating and a $40.00 price objective for the company. Evercore ISI reduced their price objective on Moderna from $50.00 to $32.00 and set an “in-line” rating on the stock in a research note on Friday, May 2nd. Finally, Royal Bank of Canada lowered their price target on Moderna from $32.00 to $28.00 and set a “sector perform” rating for the company in a report on Friday, May 2nd. Four investment analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $53.58.

Moderna Price Performance

Moderna stock opened at $28.14 on Tuesday. Moderna, Inc. has a 1-year low of $23.15 and a 1-year high of $152.28. The firm has a market capitalization of $10.88 billion, a P/E ratio of -3.03 and a beta of 1.86. The company’s 50-day moving average is $26.12 and its 200 day moving average is $33.35.

Moderna (NASDAQ:MRNA) last announced its earnings results on Thursday, May 1st. The company reported ($2.52) earnings per share for the quarter, beating the consensus estimate of ($2.92) by $0.40. Moderna had a negative net margin of 110.04% and a negative return on equity of 28.74%. The company had revenue of $108.00 million during the quarter, compared to the consensus estimate of $130.35 million. During the same period last year, the firm earned ($3.07) earnings per share. Moderna’s revenue was down 35.3% compared to the same quarter last year. Research analysts anticipate that Moderna, Inc. will post -9.61 earnings per share for the current fiscal year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.